Stryker Enters China Race With Trauson Bid
This article was originally published in The Gray Sheet
Executive Summary
The acquisition of Trauson would give Stryker deep roots into the untapped territories of China’s $1.5 billion orthopedics industry, the so-called second- and third-tier markets in lesser developed areas where multinationals haven’t been able to access.
You may also be interested in...
Will Stryker’s MAKO Purchase Bring Disruption To The Ortho Industry?
Stryker’s adoption of MAKO’s RIO (Robotic-arm Interactive Orthopedic) system could give the global medical supplier a competitive edge over other orthopedic implant makers if the company can win converts to robotic surgery by leveraging its own experience in selling capital equipment.
Will Stryker’s MAKO Purchase Bring Disruption To The Ortho Industry?
Stryker’s adoption of MAKO’s RIO (Robotic-arm Interactive Orthopedic) system could give the global medical supplier a competitive edge over other orthopedic implant makers if the company can win converts to robotic surgery by leveraging its own experience in selling capital equipment.
Stryker MAKO Purchase Could Preview Ortho’s Future
Market-leading orthopedic firms have mostly come up with incremental product updates in response to the growing tide of more technology-heavy upstarts. That is what makes Stryker’s $1.65 billion acquisition of MAKO Surgical stand out.